RE:Financials Wow!!! What were your expectations? First of all there were none, for anyone following the NRs for Therma Bright over the last year ...let alone quarter. The reason, because much of the revenue generating potential will come out in the next two quarters ....and that doesn't include AcuVid.
1. Exercising some or all of the existing options and warrants will easily cover expenses for general operations (and imho, the capital required to commence manufacturing of AcuVid). This provides security ...particularly should the FDA EUA be resolved in the next two weeks or so.
2. Commenced fulfilling first 2500 Venowave devices for DME Authority (current quarter).
3. Agreements for the manufacturing of AcuVid have been completed (current quarter)
4. eCommerce sites for Benopod and Venowave online (current quarter)
Are most investors here because of AcuVid, of course! So throwing out a revenue figure for Q1 means absolutely nothing ...because nothing was expected. If Q3 2022 has the same revenue figures ....then there'll be something to complain about ....for anyone still left. Until then let's not look for smoking guns when none have been fired.
Cheers!!!
Yamaha wrote: Revenue Q1 $253.00 Antibody sales zero Venowave sales zero Draw your own conclusions